Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteome. 2010;73:1907–20.
Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373–83.
Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001;166:7309–18.
Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, et al. Membrane-bound hsp70-engineered myeloma cell-derived exosomes stimulate more efficient cd8(+) ctl- and nk-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic hsp70. J Cell Mol Med. 2010;14:2655–66.
Laulagnier K, Vincent-Schneider H, Hamdi S, Subra C, Lankar D, Record M. Characterization of exosome subpopulations from rbl-2h3 cells using fluorescent lipids. Blood Cells Mol Dis. 2005;35:116–21.
Mazurov D, Barbashova L, Filatov A. Tetraspanin protein cd9 interacts with metalloprotease cd10 and enhances its release via exosomes. FEBS J. 2013;280:1200–13.
Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;3.
Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Exosome and exosomal microrna: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015;13:17–24.
Pant S, Hilton H, Burczynski ME. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol. 2012;83:1484–94.
Wilczynska A, Bushell M. The complexity of mirna-mediated repression. Cell Death Differ. 2015;22:22–33.
Lu F, Weidmer A, Liu CG, Volinia S, Croce CM, Lieberman PM. Epstein-barr virus-induced mir-155 attenuates nf-kappab signaling and stabilizes latent virus persistence. J Virol. 2008;82:10436–43.
Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-barr virus latent membrane protein 1 trans-activates mir-155 transcription through the nf-kappab pathway. Nucleic Acids Res. 2008;36:6608–19.
Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Hooks JJ, Redmond TM. Inflammatory cytokines regulate microrna-155 expression in human retinal pigment epithelial cells by activating jak/stat pathway. Biochem Biophys Res Commun. 2010;402:390–5.
Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, et al. Upregulation of mirna-155 promotes tumour angiogenesis by targeting vhl and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33:679–89.
Xiao H, Gu Z, Wang G, Zhao T. The possible mechanisms underlying the impairment of hif-1alpha pathway signaling in hyperglycemia and the beneficial effects of certain therapies. Int J Med Sci. 2013;10:1412–21.
Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. Exosomes are natural carriers of exogenous sirna to human cells in vitro. Cell Commun Signal. 2013;11:88.
Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, et al. Bic and mir-155 are highly expressed in hodgkin, primary mediastinal and diffuse large b cell lymphomas. J Pathol. 2005;207:243–9.
Tam W, Dahlberg JE. Mir-155/bic as an oncogenic microrna. Genes Chromosomes Cancer. 2006;45:211–2.
Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ, et al. Lack of bic and microrna mir-155 expression in primary cases of burkitt lymphoma. Genes Chromosomes Cancer. 2006;45:147–53.
Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, et al. Global microrna expression profiling uncovers molecular markers for classification and prognosis in aggressive b-cell lymphoma. Blood. 2015;125:1137–45.
Rahadiani N, Takakuwa T, Tresnasari K, Morii E, Aozasa K. Latent membrane protein-1 of epstein-barr virus induces the expression of b-cell integration cluster, a precursor form of microrna-155, in b lymphoma cell lines. Biochem Biophys Res Commun. 2008;377:579–83.
Snell CE, Turley H, McIntyre A, Li D, Masiero M, Schofield CJ, et al. Proline-hydroxylated hypoxia-inducible factor 1alpha (hif-1alpha) upregulation in human tumours. PLoS One. 2014;9, e88955.
Min JH, Yang H, Ivan M, Gertler F, Kaelin Jr WG, Pavletich NP. Structure of an hif-1alpha -pvhl complex: hydroxyproline recognition in signaling. Science. 2002;296:1886–9.
Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM. The vhl-dependent regulation of micrornas in renal cancer. BMC Med. 2010;8:64.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein vhl targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–5.
Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, et al. Structural basis for the recognition of hydroxyproline in hif-1 alpha by pvhl. Nature. 2002;417:975–8.
Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. Vhl and hif signalling in renal cell carcinogenesis. J Pathol. 2010;221:125–38.
Czyzyk-Krzeska MF, Zhang X. Mir-155 at the heart of oncogenic pathways. Oncogene. 2014;33:677–8.
de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355:1474–85.
Topouzis F, Anastasopoulos E, Augood C, Bentham GC, Chakravarthy U, de Jong PT, et al. Association of diabetes with age-related macular degeneration in the EUREYE study. Br J Ophthalmol. 2009;93:1037–41.
Hong GK, Kumar P, Wang PL, Damania B, Gulley ML, Delecluse HJ, et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol. 2005;79:13984–92.
Jones RJ, Seaman WT, Feng WT, Barlow E, Dickerson S, Delecluse HJ, et al. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int J Cancer. 2007;121:1274–81.
Slobod KS, Sandlund JT, Spiegel PH, Haik B, Hurwitz JL, Conley ME, et al. Molecular evidence of ocular Epstein-Barr virus infection. Clin Infect Dis. 2000;31:184–8.
Meckes Jr DG, Gunawardena HP, Dekroon RM, Heaton PR, Edwards RH, Ozgur S, et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A. 2013;110:E2925–33.
Andrade TA, Evangelista AF, Campos AH, Poles WA, Borges NM, Camillo CM, et al. A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly. Oncotarget. 2014;5:11813–26.
Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79:581–8.
Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15:272–84.
Yoon C, Kim D, Kim S, Park GB, Hur DY, Yang JW, et al. Mir-9 regulates the post-transcriptional level of vegf165a by targeting srpk-1 in arpe-19 cells. Graefe's Arch Clin Exp Ophthal. 2014;252:1369–76.
Kelly TJ, Souza AL, Clish CB, Puigserver P. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through mir-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol. 2011;31:2696–706.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. Mir-9, a myc/mycn-activated microrna, regulates e-cadherin and cancer metastasis. Nat Cell Biol. 2010;12:247–56.
Coolen M, Katz S, Bally-Cuif L. Mir-9: a versatile regulator of neurogenesis. Front Cell Neurosci. 2013;7:220.
Thiele S, Wittmann J, Jack HM, Pahl A. Mir-9 enhances il-2 production in activated human cd4(+) t cells by repressing blimp-1. Eur J Immunol. 2012;42:2100–8.